Loading...
•
Sep 30, 2024
Caribou Biosciences Q3 2024 Earnings Report
Caribou Biosciences reported financial results for the third quarter 2024 and reviewed recent pipeline progress.
Key Takeaways
Caribou Biosciences reported a net loss of $34.7 million for the third quarter of 2024, with licensing and collaboration revenue of $2.0 million. The company's cash, cash equivalents, and marketable securities totaled $281.0 million as of September 30, 2024, expected to fund operations into H2 2026.
Advanced four clinical-stage programs for hematologic malignancies and autoimmune diseases, with multiple clinical data reports planned for 2025.
Enrolled patients with LBCL (2L and after prior CD19-targeted therapies) with HLA matching strategy in CB-010 ANTLER Phase 1 trial; next data report planned for H1 2025.
Continued dose escalation portion of the CB-011 CaMMouflage Phase 1 trial in r/r MM with higher lymphodepletion regimen following observations of efficacy; dose escalation data to be presented H1 2025.
Cash, cash equivalents, and marketable securities expected to fund the current operating plan into H2 2026.
Caribou Biosciences
Caribou Biosciences
Forward Guidance
Caribou Biosciences plans to present data from the ANTLER clinical trial, initiate the GALLOP Phase 1 clinical trial, present dose escalation data from the CaMMouflage Phase 1 clinical trial, and provide updates on dose escalation from the AMpLify Phase 1 clinical trial.
Positive Outlook
- CB-010 ANTLER: Present data from both the additional 2L and prior CD19 relapsed LBCL patient cohorts in H1 2025.
- CB-010 ANTLER: Initiate a pivotal Phase 3 clinical trial in H2 2025 should data confirm the initial observation that partial HLA matching is associated with improved outcomes for patients.
- CB-010 GALLOP: Initiate the GALLOP Phase 1 clinical trial in adult patients with LN and ERL by year-end 2024.
- CB-011 CaMMouflage: Present dose escalation data from the ongoing CaMMouflage Phase 1 clinical trial in r/r MM in H1 2025.
- CB-012 AMpLify: Provide updates on dose escalation as the AMpLify Phase 1 clinical trial in r/r AML advances.